文献速递白血病

QUAZAR AML-001研究中复发后接受后续治疗的急性髓系白血病患者的生存结局

Survival outcomes in patients with acute myeloid leukaemia who received subsequent therapy for relapse in QUAZAR AML-001.
PubMed 文献 · Br J Haematol · 2023-11-12

该事后分析基于3期QUAZAR AML-001试验,评估口服阿扎胞苷维持治疗后接受后续抗白血病治疗患者的生存。口服阿扎胞苷组与安慰剂组分别有134/238和173/234例患者接受首次后续治疗,自随机化总生存期分别为17.8个月与12.9个月(HR 0.82,95%CI 0.64-1.04),自首次后续治疗生存期两组相似。口服阿扎胞苷维持可延长缓解持续时间且不损害挽救治疗后的生存结局。

要点

  • 口服阿扎胞苷组134/238例、安慰剂组173/234例在停药后接受首次后续治疗。
  • 自随机化总生存期口服阿扎胞苷组17.8个月 vs 安慰剂组12.9个月(HR 0.82,95%CI 0.64-1.04)。
  • 口服阿扎胞苷维持不损害后续挽救治疗后的生存结局。

核心结论

  • 口服阿扎胞苷维持治疗可延长急性髓系白血病缓解持续时间,且不损害挽救治疗后的生存结局。

研究设计与样本

  • 3期QUAZAR AML-001试验(NCT01757535)的事后分析,纳入经强化化疗后达缓解且不适合造血干细胞移植的急性髓系白血病患者。
  • 比较口服阿扎胞苷维持与安慰剂,评估停药后接受后续抗白血病治疗患者的生存结局。

主要发现

  • 口服阿扎胞苷组134/238例、安慰剂组173/234例在停药后接受首次后续治疗。
  • 接受首次后续治疗患者自随机化总生存期:口服阿扎胞苷组17.8个月 vs 安慰剂组12.9个月(HR 0.82,95%CI 0.64-1.04,中位随访56.7个月)。
  • 自首次后续治疗的总生存期两组相似。
  • 以注射用低甲基化药物作为首次后续治疗者,中位总生存期口服阿扎胞苷组8.2个月 vs 安慰剂组4.9个月(HR 0.66,95%CI 0.41-1.06)。
  • 停药后接受造血干细胞移植者共48例(口服阿扎胞苷组16/238例,安慰剂组32/234例),其中6例口服阿扎胞苷组患者仍处于首次缓解;剔除这些患者后口服阿扎胞苷组总生存获益仍持续。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In the phase 3 QUAZAR AML-001 trial (NCT01757535) of patients with acute myeloid leukaemia (AML) in remission following intensive chemotherapy (IC) and ineligible for haematopoietic stem cell transplant (HSCT), oral azacitidine (Oral-AZA) maintenance significantly prolonged overall survival (OS) versus placebo. The impact of subsequent treatment following maintenance has not been evaluated. In this post hoc analysis, OS was estimated for patients who received subsequent AML therapy, and by regimen received (IC or lower-intensity therapy). First subsequent therapy (FST) was administered after treatment discontinuation in 134/238 Oral-AZA and 173/234 placebo patients. OS from randomization in patients who received FST after Oral-AZA versus placebo was 17.8 versus 12.9 months (HR: 0.82 [95% CI: 0.64-1.04], median follow-up: 56.7 months); OS from FST was similar between arms. Among patients who received injectable hypomethylating agents as FST, median OS was 8.2 versus 4.9 months in the Oral-AZA versus placebo groups (HR: 0.66 [95% CI: 0.41-1.06]). Forty-eight patients (16/238 Oral-AZA, 32/234 placebo) received HSCT following treatment discontinuation, including six Oral-AZA patients still in first remission; Oral-AZA OS benefit persisted when censoring these patients. Oral-AZA maintenance can prolong AML remission duration without negatively impacting survival outcomes after salvage therapies.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Ravandi F, Döhner H, Wei AH, et al. Survival outcomes in patients with acute myeloid leukaemia who received subsequent therapy for relapse in QUAZAR AML-001. Br J Haematol. 2023. PMID: 37952982. doi:10.1111/bjh.19202

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。